Reportstack

PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022

 

Naperville, IL -- (ReleaseWire) -- 02/24/2014 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022 market report to its offering
PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The French obesity drug market was valued at approximately $41m in 2012. The market is a severely underserved space, with only Xenical and its generic as the sole therapy for chronic weight management. Due to the high cost of therapy, most patients have been taking generic orlistat. With a progressively more expansive view on the treatment of obesity with pharmacological intervention, The publisher forecasts the arrival of two promising therapies in 2015.

Scope

- Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the France Obesity market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in France.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/150635/pharmapoint-obesity-france-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###